AI & ML interests
Ryniant Sciences operates on a hybrid business model that merges cutting-edge innovation with broad accessibility. At its core is the proprietary Ominor Platform, which powers efficient, AI-driven drug discovery by integrating genomic, epigenomic, and clinical data. This centralized engine supports Ryniant’s specialized subsidiaries, each targeting distinct medical fields, ensuring focused expertise while benefiting from shared technology. Revenue is generated through strategic partnerships, licensing agreements, and cost-effective biologic development, while impact is amplified through open-source tools, freemium research platforms for academics, and energy-efficient infrastructure. This model balances commercial viability with ethical, inclusive science, enabling scalable innovation and equitable access to life-saving therapies worldwide. The Ominor Platform is NOT YET built which is why we require initial funding, to build the foundation of our subsidiary model Ryniant Sciences operates through a unique, modular subsidiary model that enhances both specialization and scalability. Each subsidiary is focused on a specific therapeutic area—neurological diseases, rare and neglected conditions, and dermatological disorders—allowing for deep, domain-specific research and faster innovation cycles. Despite this specialization, all subsidiaries are unified by the central Ominor Platform, Ryniant’s AI engine that drives drug discovery with unmatched efficiency. This model enables each division to move quickly and independently, while benefiting from shared data, infrastructure, and technological advancements. It reduces duplication of effort, fosters collaboration, and allows Ryniant to rapidly respond to emerging health challenges. By combining the agility of focused teams with the power of a centralized AI system, Ryniant’s subsidiary model ensures both operational efficiency and global impact.